1 month After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to health Fortune
The DNA-testing firm said in a Tuesday SEC filing, “there is substantial doubt about the company’s ability to continue.”
X